Bioniz Therapeutics

Bioniz is a clinical-stage biopharmaceutical company developing precision cytokine-targeting therapies for the treatment of immune-inflammatory diseases. Bioniz's lead candidates are multispecific inhibitors that simultaneously target multiple clinically validated disease-driving cytokines, including the potential "first-in-class" therapies BNZ-1 and BNZ-2 currently in clinical development, designed to address unmet needs across a range of immune-inflammatory indications.